ERBB2 and breast carcinoma: Concerning breast cancer, Ghassami et al. explored the efficacy of HER2-specific aptamer-guided nanoparticles in targeting SKOV-3 and MDA-MB-468 cell lines, representing HER2-positive and HER2-negative cell lines, respectively.